Enrolling pregnant women with HIV into clinical trials

Lancet HIV. 2020 May;7(5):e302-e303. doi: 10.1016/S2352-3018(20)30078-3.

Authors

Chloe Orkin¹, Sian Louise Goddard²

Affiliations

¹ Centre for Immunobiology, Queen Mary University of London, London E1 4NS, UK; Infection and Immunity, Ambrose King Centre, Royal London Hospital, London, UK. Electronic address: c.m.orkin@qmul.ac.uk.
² Infection and Immunity, Ambrose King Centre, Royal London Hospital, London, UK; The Kirby Institute, University of New South Wales, Sydney, NSW, Australia.

PMID: 32386716
DOI: 10.1016/S2352-3018(20)30078-3

No abstract available

Publication types

Comment

MeSH terms

Alkynes
Anti-Retroviral Agents
Benzoxazines
Cyclopropanes
Female
HIV Infections*
Humans
National Institute of Child Health and Human Development (U.S.)*
Pregnancy
Raltegravir Potassium
United States

Substances

Alkynes
Anti-Retroviral Agents
Benzoxazines
Cyclopropanes
Raltegravir Potassium
efavirenz